United Laboratories Secures $180 Million Upfront Payment from Novo Nordisk

The latest announcement is out from The United Laboratories International Holdings ( (HK:3933) ).

The United Laboratories International Holdings Limited announced that its subsidiary, United Biotechnology, has received an upfront payment of $180 million from Novo Nordisk under an exclusive license agreement for UBT251, a triple agonist in clinical trials for obesity and type 2 diabetes. This agreement also allows United Biotechnology to potentially receive up to $1.8 billion in milestone payments and tiered royalties based on future sales, highlighting a significant financial and strategic boost for the company in the pharmaceutical sector.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

More about The United Laboratories International Holdings

The United Laboratories International Holdings Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on developing and producing medications, with a particular emphasis on treatments for obesity, type 2 diabetes, and other related diseases.

Average Trading Volume: 15,405,063

Technical Sentiment Signal: Buy

Current Market Cap: HK$29.11B

For a thorough assessment of 3933 stock, go to TipRanks’ Stock Analysis page.